• Game Plan for the Week of June 4 Friday, 1 Jun 2007 | 6:57 PM ET

    Next week is conference week and that means companies should have big news for investors. Here’s how to play it.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Cancer and Us Friday, 1 Jun 2007 | 12:01 PM ET

    As I prepare our coverage on Monday for ASCO--the American Society of Clinical Oncology Annual Meeting--it is easy to get lost in the mind-numbing amount of data, caught up in the battles we've been drawn into with ASCO media relations and one company, in particular, that shall remain unnamed, the controversy over the ASCO data distribution policy and all of the volatility in certain stocks. But cancer touches all of us. And my family is no exception.

  • Dendreon said Thursday the U.S. Food and Drug Administration has decided that positive interim or final survival data from an ongoing trial of its Provenge cancer vaccine will satisfy the agency's earlier request for more data, sending its shares soaring.

  • European Stocks to Watch: British Energy Thursday, 31 May 2007 | 12:51 PM ET

    Shares in nuclear power group British Energy fell 2.1% despite the overall strength of the FTSE-100, following proposals from the British government to cut its stake in the nuclear power group Wednesday.

  • Dendreon: the Ride Thursday, 31 May 2007 | 10:42 AM ET

    Before the bell this morning, the ever-popular Dendreon put out a press release ahead of its presentation later today at the Bank of America Healthcare Conference in Las Vegas. You can listen to the presentation via Webcast at 1 p.m. ET. The company says that the Food and Drug Administration has confirmed that it will "accept either a positive interim or final analysis of survival" from the ongoing, larger clinical trial on Dendreon's highly controversial prostate cancer treatment Provenge.

  • Alliance Boots Shareholders Approve Takeover Bid Thursday, 31 May 2007 | 10:16 AM ET

    Alliance Boots shareholders overwhelmingly approved an 11 billion pound ($21.8 billion; 16.2 billion euros) offer from the pharmacy chain's deputy chairman and a private equity firm on Thursday.

  • Federal Judge Orders Third Trial in Case Against Merck Thursday, 31 May 2007 | 3:52 AM ET

    A federal judge has ordered a third trial in a lawsuit by a woman who blamed Merck's painkiller Vioxx for the heart attack that killed her husband.

  • Bristol-Myers Squibb has agreed to pay a $1 million criminal fine for lying to the federal government about a patent deal involving its Plavix blood thinner, the Justice Department said.

  • Wyeth Wins FDA Approval for Kidney Cancer Drug Wednesday, 30 May 2007 | 4:56 PM ET

    Wyeth's drug Torisel won U.S. approval to treat patients with a type of advanced kidney cancer known as renal cell carcinoma, the Food and Drug Administration said.

  • Has Democratic Control Been Good for Business? Wednesday, 30 May 2007 | 3:46 PM ET

    The markets always seem to like gridlock in Washington. But has Democratic control of Congress actually been good for business? Three experts discussed the minimum wage hike, prescription drug costs, and tax breaks for big oil from different ends of the spectrum on "Power Lunch."

  • Biotechnology company Novacea and drug developer Schering-Plough said they signed a licensing agreement for prostate cancer treatment candidate Asentar.

  • GlaxoSmithKline moved on Wednesday to reaffirm the safety of its troubled diabetes drug Avandia in a letter to the Lancet medical journal, reviving the group's battered stock price somewhat.

  • European Stocks to Watch: Novartis Wednesday, 30 May 2007 | 5:07 AM ET

    Swiss drug maker Novartis was the only gainer on Zurich's SMI index Wednesday, rising 0.2%, after an American federal court extended a temporary restraining order blocking a generic version of the pharmaceutical's high-blood-pressure drug Lotrel.

  • Merger news and product recalls were some of the catalysts behind the most actively traded stocks on Tuesday.

  • MedImmune Warning Won't Disrupt Vaccine Production: FDA Tuesday, 29 May 2007 | 11:20 AM ET
    FluMist(R) (Influenza Virus Vaccine Live, Intranasal) packaging.  Photo courtesy of MedImmune, Inc.  Contact Beth Malone for more information at (202) 835-9463 or beth.malone@ketchum.com. (PRNewsFoto)

    A warning issued to MedImmune over manufacturing issues at a United Kingdom plant shouldn't significantly disrupt company production of its nasal spray flu vaccine, federal health officials said.

  • Glaxo's Avandia Prescriptions Drop After Study Tuesday, 29 May 2007 | 5:00 AM ET

    Doctors in the United States have shunned GlaxoSmithKline's diabetes drug Avandia since a study was published last week linking the drug to heart-attack risk, according to daily prescription data.

  • Garnier Repondez, S'il Vous Plait Faux Pas Friday, 25 May 2007 | 10:24 AM ET
    Jean-Pierre Garnier

    If you happened to be watching CNBC's "Closing Bell" yesterday afternoon, you may have seen what we call a "promo" (short for a promotion of an upcoming story or guest) for a "First on CNBC" interview with GlaxoSmithKline CEO Jean-Pierre (JP) Garnier on today's "Closing Bell" at 3:15 ET.Since the Avandia news broke on Monday, I'd been trying to get an interview with him. He talked to The Wall Street Journal mid-week, but had yet to do a TV interview. Then, yesterday afternoon I got a call from his British PR person telling me that Garnier would like to come on CNBC on Friday. She said he was flying to the States from Europe last night and that we could do a live, one-on-one interview with him at or near the company's U.S. headquarters in Pennsylvania.

  • Breaking Down the Dow Thursday, 24 May 2007 | 6:10 PM ET

    Cramer thinks this index will climb another thousand points by the end of the year. Owning the stocks that should get it there could do wonders for your portfolio.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Contest Finalist Tepichin: "Going For the Fences" Thursday, 24 May 2007 | 4:22 PM ET

    John Tepichin says he's all in on his one stock--Biomarin--and "going for the fences," as the Million Dollar Portfolio Challenge is coming to a close. The contest ends Friday at the closing bell. John's stock was down some 2 percent today, but he says he has some "strong" ideas for Friday. He's currently in 15th place out of 20 finalists--so John better have some pretty good "fence going" ideas.

  • Lipitor: Loser Thursday, 24 May 2007 | 3:16 PM ET

    Big pharma analysts keep close tabs on prescription trends. Many of them issue weekly reports to clients about what's up, what's down, what's holding steady. Investors use the data as a leading indicator for what quarterly sales and profits might look like. So, check out what A.G. Edwards' Joe Tooley is writing in his most recent "Weekly Prescription Trends" report.Tooley titles it, "Lipitor Continues to Decline, Can Simvastatin (the generic version of Zocor) Surpass It?"

Most Popular Video

Wednesday, 23 Apr 2014 | 12:00 AM ET

Most people probably don't want their six-figure sports cars all marked up, unless it's been marked up by the world's best basketball players. This one-of-a-kind 2002 Aston Martin Vanquish is the only car on the planet to have 50 signatures on it from 50 basketball Hall of Famers, increasing its value over 500 percent.

Wednesday, 23 Apr 2014 | 1:00 PM ET

CNBC's Kelli Grant talks about the types of protection available to credit and debit card holders in the transition to a cashless society.

Wednesday, 23 Apr 2014 | 12:00 PM ET

Rumors of a delayed Apple iPhone 6 product launch and a larger display screen are swirling about the technosphere, with Lindsey Turrentine, CNET editor-in-chief.